A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy

NCT03301207 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

DRUG: Ibrutinib
DRUG: OC: Ethinylestradiol (EE) 30 mcg and Levonorgestrel (LN) 150 mcg
DRUG: Bupropion
DRUG: Midazolam

Sponsor

Janssen Research & Development, LLC